Genesis Therapeutics

Claim Tool

Last updated: January 26, 2026

Reviews

0 reviews

What is Genesis Therapeutics?

Genesis Therapeutics is a biotech leader in molecular AI that unites deep learning and physics-based machine learning in its proprietary GEMS platform and Pearl foundation model to unlock tough protein targets and rapidly discover highly potent, selective small-molecule therapeutics across multiple disease areas. With state-of-the-art protein–ligand prediction, industry-leading speed, and a growing pipeline, Genesis partners with pharma while advancing its own AI-enabled medicines.

Category

Genesis Therapeutics's Top Features

Advanced molecular AI platform integrating deep learning and physics-based ML

Proprietary GEMS platform for AI-driven molecular design

Pearl foundation model for protein–ligand structure prediction

Reported performance exceeding AlphaFold 3 on key protein–ligand benchmarks

Focus on unlocking tough, chemically complex protein targets

Industry-leading speed with high potency and selectivity in discovery workflows

Scalable small-molecule discovery across large chemical spaces

Active internal pipeline across multiple therapeutic areas (e.g., immunology, inflammation)

Dedicated AI research advancing state-of-the-art molecular modeling

Drug pipeline development enabled by AI-guided design and triage

Protein–ligand binding pose prediction to guide medicinal chemistry

Strategic AI-focused collaborations (e.g., with Incyte)

Founded in 2019 with strong investor backing (a16z, Fidelity, BlackRock, NVIDIA)

Experienced leadership with deep pharma and AI expertise

Biotech focus on AI-enabled small-molecule therapeutics

Frequently asked questions about Genesis Therapeutics

Genesis Therapeutics's pricing

Share

Customer Reviews

Share your thoughts

If you've used this product, share your thoughts with other customers

Recent reviews

News

    Top Genesis Therapeutics Alternatives

    Use Cases

    Medicinal chemists

    Rapidly optimize potency and selectivity using AI-guided design and structure–activity insights from GEMS.

    Computational biologists

    Predict protein–ligand structures at scale with Pearl to prioritize designs and de-risk experiments.

    Drug discovery teams

    Unlock hard protein targets previously considered intractable to expand the addressable target space.

    Pharma R&D leaders

    Accelerate hit finding and lead optimization to compress cycle times and improve portfolio velocity.

    Biotech startups

    Leverage platform expertise via partnerships to build high-quality pipelines with fewer resources.

    Structural biologists

    Generate high-confidence binding poses to inform assay design and crystallography or cryo-EM efforts.

    Project managers

    Triage large design spaces efficiently, focusing wet-lab effort on the most promising candidates.

    BD and alliance teams

    Structure AI-driven collaborations (e.g., with Incyte) to pursue new small-molecule programs jointly.

    Therapeutic area leads

    Apply molecular AI to immunology and inflammation targets to advance differentiated candidates.

    Investors and advisors

    Evaluate platform differentiation, benchmark leadership, and pipeline scalability in molecular AI.